Clinical Paper On Treatment Of Burns Highlights Effectiveness Of Misonix Incorporated SonicOne In Burn Center Operating Room

FARMINGDALE, N.Y., Nov. 13, 2014 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, participated in the 42^nd Annual Eastern Great Lakes Burn Study Group Meeting in Pittsburgh, PA held October 16-17, 2014.

Misonix exhibited at the meeting and offered surgeons hands on training with its SonicOne O.R. Ultrasonic Surgical Debridement System. The SonicOne O.R. is an innovative surgical device that allows surgeons to address the challenges chronic wounds present to them, the patient, and the health-care system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process. Use of the SonicOne O.R. system provides controlled tissue removal, decreased healing times, reduced bleeding and a reduction of biofilm.

The conference, hosted by the University of Pittsburgh Medical Center-Mercy Burn Center, was well-attended by physicians, nurses, occupational therapists and other wound care professionals from throughout Pennsylvania and the surrounding states.  Dr. Ariel Aballay, Medical Director of the West Penn Burn Center et al., concluded in a clinical abstract entitled An Alternative Method of Debridement for Complex Burn Wounds, that "The surgical debrider (Misonix SonicOne O.R.) is a useful tool for management of burns, in addition to other types of wounds. Using this system in burns allowed us to debride this wound twice with minimal impact to healthy tissue, including residual autograft tissue."

Dr. Aballay further concluded, "With new technologies like the SonicOne O.R. we are now able to perform very delicate debridements which would be very difficult with previous technologies available to us.  The tissue selectivity of the ultrasound allows us to remove nonviable tissue while at the same time preserve the healthy tissue with minimal bleeding.  We are very encouraged by our early experiences with the exciting new technology."

"We are encouraged by the study results reported by Dr. Aballay and his colleagues on SonicOne as this further affirms the growing evidence in the surgical community that Misonix ultrasound technology is an effective tool in the treatment of burn wounds and other types of complex wounds," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

SOURCE Misonix, Inc.